Skip to content

A randomized controlled trial of the detection rate of early gastric cancer by painless endoscopy assisted by artificial intelligence (AI) and traditional painless endoscopy in the middle and high-risk groups of gastric cancer

A randomized controlled trial of the detection rate of early gastric cancer by painless endoscopy assisted by artificial intelligence (AI) and traditional painless endoscopy in the middle and high-risk groups of gastric cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033775
Enrollment
Unknown
Registered
2020-06-11
Start date
2020-11-30
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer

Interventions

experimental group:AI assisted painless gastroscope precision examination
control group:Traditional painless gastroscope precision examination

Sponsors

Xi'an Gaoxin Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Over 18 years of age (inclusive); 2. Gastroscopy is needed to further clarify the characteristics of upper gastrointestinal diseases; 3. Painless gastroscopy; 4. Ability to read, understand and sign the informed consent; 5. The researchers believe that the subjects can understand the procedures of the clinical study and are willing and able to complete all the study procedures and follow-up visits to cooperate with the study.

Exclusion criteria

Exclusion criteria: 1. Has participated in other clinical trials, signed informed consent and is in the follow-up period of other clinical trials; 2. Has participated in clinical trials of drugs and is in the elution period of experimental drugs or control drugs; 3. Drug or alcohol abuse or psychological disorder in the last 5 years; 4. Pregnant or lactating women; 5. Subjects previously diagnosed with gastric stump; 6. Previous history of anaesthesia drug allergy; 7. Previous history of allergy to antispasmodic; 8. The researchers did not consider the subjects suitable for painless gastroscopy; 9. The researchers determined that the subjects were not eligible to participate in clinical trials for high-risk diseases or other special conditions.

Design outcomes

Primary

MeasureTime frame
histopathology;the detection rate of early gastric cancer;

Secondary

MeasureTime frame
the detection rate of precancerous lesions;

Countries

China

Contacts

Public ContactSong Ying

Xi'an Gaoxin Hospital

songying688@163.com+86 13991919093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026